Study Links Psychedelics and Ketamine to Common Neuroimmune Signals

Groundbreaking research combines patient-derived cells, proteomics, and clinical ketamine data to identify shared neuroimmune biomarkers underlying rapid antidepressant responses. The study reveals that both psychedelic compounds and ketamine activate similar immune signaling pathways in the brain, offering crucial insights into how these treatments produce fast-acting antidepressant effects. These findings could enable identification of biomarkers to predict patient response and develop more effective rapid-acting treatments for major depressive disorder. The research bridges the gap between traditional pharmacology and emerging psychedelic therapeutics, advancing precision medicine approaches for treatment-resistant depression.